logo
logo

Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million

Jul 16, 2020•about 5 years ago

Amount Raised

$5 Million

Round Type

series b

Schlieren

Description

Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today that it has successfully completed a CHF 7.5 million Series B equity financing round.

Company Information

Company

Virometix

Location

Schlieren, Zurich, Switzerland

About

Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.